Oncology Vol 27 No 10

Balancing Benefits and Risks of Melanoma Treatment: What Do We Tell Our Patients?

October 15, 2013

All of us treating patients with melanoma must educate our patients about the importance of participating in clinical trials with these new agents so that we can systematically validate the benefits and risks of these agents in prospectively defined patient settings.

An Argument for Aggressive Resection in Melanoma

October 15, 2013

Any minimization of therapy in the name of reducing morbidity requires careful consideration. Reducing morbidity in melanoma is certainly a laudable goal, but locoregional disease control and cure must remain our primary objectives.

Cancer Care and Accountable Care Organizations: The Unknown Patient Experience Landscape

October 15, 2013

ACOs can provide the structure, but it’s up to the stakeholders to establish mutually agreeable goals for this new care delivery model. Achieving these goals will require a different set of dialogues and conversations among stakeholders, and patients and their advocates must have seats at the table.

PSA Screening: The Case in Favor

October 15, 2013

The facts presented about screening should be tailored to the patient’s exact situation, and the patient’s values should be used to guide the final decision. For younger, healthy men, PSA screening should continue to be strongly considered.

PSA Screening: Good Evidence Shows Little Benefit, Significant Harms

October 15, 2013

The Task Force’s recommendation against PSA screening for prostate cancer is based on the best available science and the knowledge that, while we all want to prevent suffering and death from prostate cancer, PSA screening simply does not get us there.

PSA Screening in Men Newly Diagnosed With Colorectal Cancer: Each According to His Group’s Means?

October 15, 2013

Once a patient has been appropriately educated by an informed healthcare provider about the possible benefits of PSA screening, then patient preference as part of shared decision making regarding PSA screening should be considered in all cases.

PSA Screening for Colorectal Cancer Patients: Proceeding With Caution

October 15, 2013

It may be appropriate to offer prostate cancer screening to carefully selected men with a previous history of colorectal cancer. However, the risks and benefits of establishing the diagnosis in this setting need to be considered and discussed with them.

Should All Colorectal Cancer Patients Over Age 60 Be Screened for Prostate Cancer?

October 15, 2013

Not all patients with colorectal cancer are candidates for such screening, however, as a remaining life expectancy of at least 10 years is generally required in order for PSA screening to yield a significant mortality benefit.

Kinder, Gentler Cancer Therapy: Not So Fast

October 15, 2013

Kinder, gentler cancer therapy is neither of those things if it fails to be as effective in controlling the cancer. When an area of completely clinically regressed cancer is excised, there is commonly residual cancer present.

Pelvic Radiation Therapy for Early Endometrial Cancer: Careful Selection Is Key

October 15, 2013

Future directions, including nomograms, multi-modality approaches, and more individualized patient care based on genomic profiles, may help to tailor each endometrial cancer patient’s therapy to her individual risk.